Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | RAB9A | P51151 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.74 |
| ▸ | MEN1 | O00255 | 5/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.73 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.73 |
| ▸ | VCP | P55072 | 1/20 | 0.73 |
| ▸ | ESR1 | P03372 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | HTT | P42858 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | GAA | P10253 | 2/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.71 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.65 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6926815 | 0.92 | ALOX5 (0.85) | MAPTRAB9ASMN1; SMN2NPC1TDP1 | |
| SCHEMBL1820221 | 0.88 | NPY5R (0.88) | MAPTRAB9ASMN1; SMN2NPC1TDP1 | |
| SCHEMBL24997146 | 0.86 | MAPT (0.74) | MAPTRAB9ASMN1; SMN2NPC1TDP1 | |
| SCHEMBL31126428 | 0.85 | ALOX5 (0.78) | MAPTRAB9ASMN1; SMN2NPC1TDP1 | |
| SCHEMBL12297865 | 0.85 | ALOX5 (0.74) | MAPTRAB9ASMN1; SMN2NPC1TDP1 | |
| SCHEMBL31126461 | 0.85 | ALOX5 (0.74) | MAPTRAB9ASMN1; SMN2NPC1TDP1 | |
| SCHEMBL838274 | 0.85 | ALOX5 (0.74) | MAPTRAB9ASMN1; SMN2NPC1TDP1 | |
| SCHEMBL1888054 | 0.85 | ALOX5 (0.78) | MAPTRAB9ASMN1; SMN2NPC1TDP1 | |
| SCHEMBL18083871 | 0.85 | MAPT (0.74) | MAPTRAB9ASMN1; SMN2NPC1TDP1 | |
| SCHEMBL2755675 | 0.85 | ALOX5 (0.74) | MAPTRAB9ASMN1; SMN2NPC1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9974795-B2 | Anticancer agent composition | CARNA BIOSCIENCES, INC. (JP) | 2018-05-22 | — | — | US | claimed |
| US-20170065609-A1 | ANTICANCER AGENT COMPOSITION | CARNA BIOSCIENCES, INC. (JP) | 2017-03-09 | — | — | US | claimed |
| EP-3100742-A1 | ANTICANCER AGENT COMPOSITION | Carna Biosciences Inc. (JP) | 2016-12-07 | — | — | EP | claimed |
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-05-05 | — | — | US | claimed |
| EP-1135126-A4 | MYT1 KINASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-04-02 | — | — | EP | claimed |
| EP-1135126-A2 | MYT1 KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2001-09-26 | — | — | EP | claimed |
| WO-2000033837-A2 | MYT1 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-06-15 | — | — | WO | claimed |
| EP-3100742-B1 | ANTICANCER AGENT COMPOSITION COMPRISING A CDC7 INHIBITOR AND A WEE1 INHIBITOR | CARNA BIOSCIENCES INC (JP) | 2020-05-20 | — | — | EP | disclosed |
| US-9974795-B2 | Anticancer agent composition | CARNA BIOSCIENCES, INC. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-20170065609-A1 | ANTICANCER AGENT COMPOSITION | CARNA BIOSCIENCES, INC. (JP) | 2017-03-09 | — | — | US | disclosed |
| EP-3100742-A1 | ANTICANCER AGENT COMPOSITION | Carna Biosciences Inc. (JP) | 2016-12-07 | — | — | EP | disclosed |
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-05-05 | — | — | US | disclosed |
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-05-05 | — | — | US | disclosed |
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-05-05 | — | — | US | disclosed |
| WO-2009114552-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170065609-A1 | ANTICANCER AGENT COMPOSITION | CDC7, CDC16, MCM7 | MAPT 3662/4885RAB9A 3325/4885SMN1; SMN2 3548/4885 |
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | VHL, TP53, BECN1 | MAPT 2506/4885RAB9A 508/4885SMN1; SMN2 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.